Oral Oresentation 4

3:42 PM - 3:48 PM JST(6:42 AM - 6:48 AM UTC)

[O04-03] Efficacy of mirikizumab in comparison to ustekinumab in East Asian patients with moderately-to-severely active Crohn's disease: post hoc sub-analysis of the phase 3 VIVID-1 study

*Minhu Chen¹, Xiang Gao², Vipul Jairath³, Hong Guo⁴, Zhaotao Li⁵, Tae Oh Kim⁶, Wentao Luo⁷, Masaru Tanaka⁸, Jiawei Xu⁷, Frederick Durand⁹, Tadakazu Hisamatsu¹⁰ (1. The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, 2. The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, 3. Western University, London, ON, Canada, 4. Department of Gastroenterology, Chongqing General Hospital, Chongqing University, Chongqing, China, 5. The First People's Hospital of Foshan, Foshan, China, 6. Inje University Haeundae Paik Hospital, Busan, South Korea, 7. Eli Lilly and Company, Shanghai, China , 8. Eli Lilly Japan K.K., Kobe, 9. Eli Lilly and Company, Indianapolis, IN, USA, 10. Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan)

Password required to view

Enter the password to view the abstracts.
The password will be emailed to those who have completed the registration.